Sirtex Medical Limited : Sirtex Medical Inc. Launches SIR-Spheres® Microspheres Therapy in Latin America

Company Announces First SIR-Spheres Microspheres Treatment at Hospital Italiano de Buenos Aires in Argentina

Sirtex Medical Inc., a subsidiary of Sirtex Medical Limited (ASX:SRX), announced today the treatment of the first patients in Latin America. Sirtex's SIR-Spheres^® microspheres are now available to treat inoperable liver tumors in Argentina. The first SIR-Spheres microspheres treatment took place on October 10 at the Hospital Italiano de Buenos Aires which is the first center to offer the therapy in Latin America.

"Sirtex's expansion into Latin America is a pivotal step in our strategy to bring the SIR-Spheres microspheres treatment to more patients who will benefit from this technology," said Michael Mangano, president of Sirtex Medical Inc. "In the past, patients with inoperable liver tumors in Latin America have had few options and Selective Internal Radiation Therapy (SIRT) has not been available. We look forward to working with our partner physicians and hospitals to help implement SIR-Spheres microspheres programs and expand the level of care they are able to provide in this region."

In addition to the 2,000 Argentinians who will be diagnosed with primary liver cancer each year, over 5,000 people diagnosed with colorectal cancer will see their cancer spread to the liver. Many patients with cancer in their liver will die of the disease.¹

"The radioactive microspheres are a powerful resource for treating unresectable primary and secondary tumors," said Dr. Ricardo García-Mónaco, Head of Angiography and Endovascular Therapy, Hospital Italiano de Buenos Aires. "This new treatment is used singly or combined with other therapies, providing excellent results and allowing patients to maintain a good quality of life."

Sirtex recently received regulatory approval for SIR-Spheres microspheres from the National Administration of Drugs, Food & Medical Technology (ANMAT). Sirtex will provide training and support for hospitals in Latin America to administer SIR-Spheres microspheres. The Company anticipates expanding the availability of SIR-Spheres microspheres in additional centers in Argentina and countries in Latin America in the upcoming months.

The announcement comes at a time when the Company is experiencing record growth. Globally Sirtex reported revenue growth of 18 percent to $86 million with record dose sales of 6,141 worldwide, up 23 percent for the most recent fiscal year ended June 30, 2012. U.S. dose sales of more than 3,900 units contributed more than 63 percent of total global dose sales. Total revenue from sales of SIR-Spheres microspheres in the U.S. grew 32 percent to $59 million for fiscal year 2012.

For more information visit www.Sirtex.com or find the latest updates on the SIR-Spheres microspheres Facebook page (www.Facebook.com/SIRSpheresmicrospheres).

About Selective Internal Radiation Therapy using SIR-Spheres microspheres

Selective Internal Radiation Therapy (SIRT), also known as radioembolization, is a proven technology for inoperable liver cancer that delivers doses of radiation directly to the site of tumors. In a minimally invasive treatment, millions of radioactive SIR-Spheres microspheres are infused via a catheter into the liver where they selectively target liver tumors with a dose of internal radiation up to 40 times higher than conventional radiotherapy, while sparing healthy tissue.

Clinical studies have confirmed that patients with metastatic colorectal cancer treated with SIR-Spheres microspheres have response rates higher than with other forms of treatment, resulting in increased life expectancy, greater periods without tumor activity and improved quality of life. SIRT has been found to shrink liver tumors more than chemotherapy alone.

SIR-Spheres microspheres are approved for use in Australia, the United States of America (FDA PMA approval), the European Union (CE Mark) and Argentina (ANMAT). Additionally, SIR-Spheres microspheres are supplied in countries such as Hong Kong, Malaysia, Singapore, Thailand, Taiwan, India, Israel, and Turkey. Available at more than 500 treatment centers, over 25,000 doses of SIR-Spheres microspheres have been supplied worldwide.

For more information, visit www.sirtex.com.

SIR-Spheres^® is a registered trademark of Sirtex SIR-Spheres Pty Ltd

REFERENCES
¹ World health Organization: Cancer Incidence, Mortality and Prevalence Worldwide in 2008 http://globocan.iarc.fr/

Fleishman-Hillard on behalf of Sirtex Medical
Andrea Moody, 919-457-0743
Andrea.Moody@fleishman.com

Partner Area